215 related articles for article (PubMed ID: 19029227)
1. Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers.
Peyrottes I; Navarro V; Ondo-Mendez A; Marcellin D; Bellanger L; Marsault R; Lindenthal S; Ettore F; Darcourt J; Pourcher T
Eur J Endocrinol; 2009 Feb; 160(2):215-25. PubMed ID: 19029227
[TBL] [Abstract][Full Text] [Related]
2. Rapid communication: predominant intracellular overexpression of the Na(+)/I(-) symporter (NIS) in a large sampling of thyroid cancer cases.
Dohán O; Baloch Z; Bánrévi Z; Livolsi V; Carrasco N
J Clin Endocrinol Metab; 2001 Jun; 86(6):2697-700. PubMed ID: 11397873
[TBL] [Abstract][Full Text] [Related]
3. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma.
Liu YY; Morreau H; Kievit J; Romijn JA; Carrasco N; Smit JW
Eur J Endocrinol; 2008 Mar; 158(3):375-84. PubMed ID: 18299472
[TBL] [Abstract][Full Text] [Related]
4. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
[TBL] [Abstract][Full Text] [Related]
5. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
[TBL] [Abstract][Full Text] [Related]
6. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
7. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
Carvalho DP; Ferreira AC
Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
[TBL] [Abstract][Full Text] [Related]
8. Sodium iodide symporter and pendrin expression in human thyroid tissues.
Mian C; Lacroix L; Alzieu L; Nocera M; Talbot M; Bidart JM; Schlumberger M; Caillou B
Thyroid; 2001 Sep; 11(9):825-30. PubMed ID: 11575851
[TBL] [Abstract][Full Text] [Related]
9. Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein.
Tonacchera M; Viacava P; Agretti P; de Marco G; Perri A; di Cosmo C; de Servi M; Miccoli P; Lippi F; Naccarato AG; Pinchera A; Chiovato L; Vitti P
J Clin Endocrinol Metab; 2002 Jan; 87(1):352-7. PubMed ID: 11788674
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas.
Saito T; Endo T; Kawaguchi A; Ikeda M; Katoh R; Kawaoi A; Muramatsu A; Onaya T
J Clin Invest; 1998 Apr; 101(7):1296-300. PubMed ID: 9525971
[TBL] [Abstract][Full Text] [Related]
11. Hydrocortisone and purinergic signaling stimulate sodium/iodide symporter (NIS)-mediated iodide transport in breast cancer cells.
Dohán O; De la Vieja A; Carrasco N
Mol Endocrinol; 2006 May; 20(5):1121-37. PubMed ID: 16439463
[TBL] [Abstract][Full Text] [Related]
12. Subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues.
Kollecker I; von Wasielewski R; Langner C; Müller JA; Spitzweg C; Kreipe H; Brabant G
Thyroid; 2012 May; 22(5):529-35. PubMed ID: 22545753
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
[TBL] [Abstract][Full Text] [Related]
14. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
15. A novel therapeutic strategy for medullary thyroid cancer based on radioiodine therapy following tissue-specific sodium iodide symporter gene expression.
Cengic N; Baker CH; Schütz M; Göke B; Morris JC; Spitzweg C
J Clin Endocrinol Metab; 2005 Aug; 90(8):4457-64. PubMed ID: 15941870
[TBL] [Abstract][Full Text] [Related]
16. Alpha-lipoic acid induces sodium iodide symporter expression in TPC-1 thyroid cancer cell line.
Choi HJ; Kim TY; Ruiz-Llorente S; Jeon MJ; Han JM; Kim WG; Shong YK; Kim WB
Nucl Med Biol; 2012 Nov; 39(8):1275-80. PubMed ID: 22995901
[TBL] [Abstract][Full Text] [Related]
17. The Na+/I- symporter mediates iodide uptake in breast cancer metastases and can be selectively down-regulated in the thyroid.
Wapnir IL; Goris M; Yudd A; Dohan O; Adelman D; Nowels K; Carrasco N
Clin Cancer Res; 2004 Jul; 10(13):4294-302. PubMed ID: 15240514
[TBL] [Abstract][Full Text] [Related]
18. Iodide symporter gene expression in human thyroid tumors.
Arturi F; Russo D; Schlumberger M; du Villard JA; Caillou B; Vigneri P; Wicker R; Chiefari E; Suarez HG; Filetti S
J Clin Endocrinol Metab; 1998 Jul; 83(7):2493-6. PubMed ID: 9661633
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas.
Gérard AC; Daumerie C; Mestdagh C; Gohy S; De Burbure C; Costagliola S; Miot F; Nollevaux MC; Denef JF; Rahier J; Franc B; De Vijlder JJ; Colin IM; Many MC
J Clin Endocrinol Metab; 2003 Oct; 88(10):4977-83. PubMed ID: 14557483
[TBL] [Abstract][Full Text] [Related]
20. A Carboxy-Terminal Monoleucine-Based Motif Participates in the Basolateral Targeting of the Na+/I- Symporter.
Martín M; Modenutti CP; Peyret V; Geysels RC; Darrouzet E; Pourcher T; Masini-Repiso AM; Martí MA; Carrasco N; Nicola JP
Endocrinology; 2019 Jan; 160(1):156-168. PubMed ID: 30496374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
